LT2271658T - Antioksidantai uždegimo moduliatoriai:oleanolio rūgšties c-17 patvirtinti dariniai - Google Patents
Antioksidantai uždegimo moduliatoriai:oleanolio rūgšties c-17 patvirtinti dariniaiInfo
- Publication number
- LT2271658T LT2271658T LTEP09732769.6T LT09732769T LT2271658T LT 2271658 T LT2271658 T LT 2271658T LT 09732769 T LT09732769 T LT 09732769T LT 2271658 T LT2271658 T LT 2271658T
- Authority
- LT
- Lithuania
- Prior art keywords
- acid derivatives
- oleanolic acid
- antioxidant inflammation
- inflammation modulators
- homologated oleanolic
- Prior art date
Links
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical class C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 title 1
- 206010061218 Inflammation Diseases 0.000 title 1
- 239000003963 antioxidant agent Substances 0.000 title 1
- 230000003078 antioxidant effect Effects 0.000 title 1
- 230000004054 inflammatory process Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/45—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C255/47—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of rings being part of condensed ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
- C07C53/15—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing halogen
- C07C53/16—Halogenated acetic acids
- C07C53/18—Halogenated acetic acids containing fluorine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
- C07D303/02—Compounds containing oxirane rings
- C07D303/36—Compounds containing oxirane rings with hydrocarbon radicals, substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
- C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D317/28—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
- C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Virology (AREA)
- Ophthalmology & Optometry (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Molecular Biology (AREA)
- Psychology (AREA)
- Communicable Diseases (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US4636608P | 2008-04-18 | 2008-04-18 | |
US11129408P | 2008-11-04 | 2008-11-04 | |
PCT/US2009/041176 WO2009129548A1 (en) | 2008-04-18 | 2009-04-20 | Antioxidant inflammation modulators: c-17 homologated oleanolic acid derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
LT2271658T true LT2271658T (lt) | 2017-02-27 |
Family
ID=40852224
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
LTEP09732769.6T LT2271658T (lt) | 2008-04-18 | 2009-04-20 | Antioksidantai uždegimo moduliatoriai:oleanolio rūgšties c-17 patvirtinti dariniai |
Country Status (28)
Country | Link |
---|---|
US (3) | US7943778B2 (lt) |
EP (1) | EP2271658B1 (lt) |
JP (2) | JP5588966B2 (lt) |
KR (2) | KR20110010611A (lt) |
CN (2) | CN104250280A (lt) |
AU (2) | AU2009237581C1 (lt) |
BR (1) | BRPI0911422B8 (lt) |
CA (1) | CA2721666C (lt) |
CO (1) | CO6311107A2 (lt) |
CY (1) | CY1118475T1 (lt) |
DK (1) | DK2271658T3 (lt) |
EA (1) | EA020156B1 (lt) |
ES (1) | ES2613964T3 (lt) |
HK (2) | HK1152713A1 (lt) |
HR (1) | HRP20170102T1 (lt) |
HU (1) | HUE033288T2 (lt) |
IL (1) | IL208759B (lt) |
LT (1) | LT2271658T (lt) |
ME (1) | ME02751B (lt) |
MX (1) | MX2010011439A (lt) |
NZ (1) | NZ588711A (lt) |
PL (1) | PL2271658T3 (lt) |
PT (1) | PT2271658T (lt) |
RS (1) | RS55631B1 (lt) |
SI (1) | SI2271658T1 (lt) |
TW (1) | TWI584808B (lt) |
WO (1) | WO2009129548A1 (lt) |
ZA (1) | ZA201007589B (lt) |
Families Citing this family (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6326507B1 (en) | 1998-06-19 | 2001-12-04 | Trustees Of Dartmouth College | Therapeutic compounds and methods of use |
CN101155579B (zh) | 2005-02-03 | 2012-10-31 | 综合医院公司 | 治疗吉非替尼耐药性癌症的方法 |
CN103110948A (zh) | 2005-11-04 | 2013-05-22 | 惠氏公司 | mTOR抑制剂、赫赛汀和/或HKI-272的抗肿瘤组合 |
US8022216B2 (en) | 2007-10-17 | 2011-09-20 | Wyeth Llc | Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof |
WO2009089545A1 (en) | 2008-01-11 | 2009-07-16 | Reata Pharmaceuticals, Inc. | Synthetic triterpenoids and methods of use in the treatment of disease |
MX2010011435A (es) | 2008-04-18 | 2011-01-25 | Reata Pharmaceuticals Inc | Compuestos que incluyen un nucleo farmaceutico antiinflamatorio y sus metodos de uso. |
CA2721838C (en) | 2008-04-18 | 2017-05-23 | Reata Pharmaceuticals, Inc. | Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at c-17 |
BRPI0911422B8 (pt) | 2008-04-18 | 2021-05-25 | Reata Pharmaceuticals Inc | compostos moduladores inflamatórios antioxidantes, composição farmacêutica e usos dos mesmos |
CN102164941B (zh) | 2008-04-18 | 2015-05-27 | 里亚塔医药公司 | 抗氧化剂炎症调节剂:具有饱和c环的齐墩果酸衍生物 |
WO2009146216A2 (en) | 2008-04-18 | 2009-12-03 | Reata Pharmaceuticals. Inc. | Antioxidant inflammation modulators: novel derivatives of oleanolic acid |
KR20130088908A (ko) | 2008-06-17 | 2013-08-08 | 와이어쓰 엘엘씨 | Hki-272 및 비노렐빈을 함유하는 항신생물성 조합물 |
JP5758801B2 (ja) * | 2008-07-22 | 2015-08-05 | トラスティーズ・オブ・ダートマス・カレッジTrustees of Dartmouth College | 単環式シアノエノンおよびその使用方法説明 |
CN109464445A (zh) | 2008-08-04 | 2019-03-15 | 惠氏有限责任公司 | 4-苯胺基-3-氰基喹啉和卡培他滨的抗肿瘤组合 |
ES2941894T3 (es) | 2009-04-06 | 2023-05-26 | Wyeth Llc | Régimen de tratamiento que utiliza neratinib contra el cáncer de mama |
KR101819699B1 (ko) | 2010-04-12 | 2018-01-17 | 리아타 파마슈티컬즈, 아이엔씨. | 항산화성 염증 조절제를 이용하여 비만을 치료하는 방법 |
CN102985438B (zh) * | 2010-06-04 | 2016-05-18 | 百时美施贵宝公司 | 作为hiv成熟抑制剂的经修饰c-3桦木酸衍生物的c-28酰胺 |
CN103038245B (zh) * | 2010-06-04 | 2015-03-25 | 百时美施贵宝公司 | 作为hiv成熟抑制剂的c-3经修饰的桦木酸衍生物 |
US8513436B2 (en) | 2010-12-17 | 2013-08-20 | Reata Pharmaceuticals, Inc. | Pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators |
MX348862B (es) | 2011-03-11 | 2017-07-03 | Reata Pharmaceuticals Inc | Derivados c4-monometil triterpenoides y sus metodos de uso. |
WO2013163344A1 (en) | 2012-04-27 | 2013-10-31 | Reata Pharmaceuticals, Inc. | 2.2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereof |
US8921419B2 (en) | 2012-05-08 | 2014-12-30 | Trustees Of Dartmouth College | Triterpenoids and compositions containing the same |
US8981144B2 (en) | 2012-05-08 | 2015-03-17 | Trustees Of Dartmouth College | Method for synthesizing 2-cyano-3,12-dioxoolean-1, 9(11)-dien-28-oic acid methyl ester and derivatives thereof |
US9556222B2 (en) | 2012-06-15 | 2017-01-31 | Reata Pharmaceuticals, Inc. | A-ring epoxidized triterpenoid-based anti-inflammation modulators and methods of use thereof |
EP2892910B1 (en) * | 2012-09-10 | 2016-09-07 | AbbVie Inc. | Glycyrrhetinic acid derivatives with anti-inflammatory activity |
US9512094B2 (en) | 2012-09-10 | 2016-12-06 | Reata Pharmaceuticals, Inc. | C17-heteroaryl derivatives of oleanolic acid and methods of use thereof |
DK2892912T3 (da) * | 2012-09-10 | 2019-06-24 | Reata Pharmaceuticals Inc | C17-alkandiyl og alkenediylderivater af oleanolsyre og fremgangsmåder til anvendelse deraf |
SI2892911T1 (sl) * | 2012-09-10 | 2017-12-29 | Reata Pharmaceuticals, Inc. | C17-heteroarilni derivati oleanolne kisline in postopki njihove uporabe |
US9278912B2 (en) | 2012-09-10 | 2016-03-08 | Reata Pharmaceuticals, Inc. | C13-hydroxy derivatives of oleanolic acid and methods of use thereof |
CN102861037B (zh) * | 2012-10-26 | 2014-04-16 | 吴俊华 | Gypensapogenin B在治疗动脉粥样硬化药物中的应用 |
CN103800902A (zh) * | 2012-11-14 | 2014-05-21 | 中国药科大学 | 含有齐墩果酸的药物组合物及其医药用途 |
WO2014091467A2 (en) * | 2012-12-16 | 2014-06-19 | Mahesh Kandula | Compositions and methods for the treatment of autoimmune diseases and inflammation |
WO2014148455A1 (ja) | 2013-03-19 | 2014-09-25 | 第一三共株式会社 | テルペノイド誘導体 |
TWI649330B (zh) | 2013-04-24 | 2019-02-01 | 艾伯維有限公司 | 甲基巴多索龍之2,2-二氟丙醯胺衍生物、其多晶形及其使用方法 |
BR112016003454B1 (pt) | 2013-08-23 | 2023-02-14 | Reata Pharmaceuticals, Inc. | Uso de composto de metil bardoxolona |
US10189791B2 (en) | 2014-08-26 | 2019-01-29 | Trustees Of Dartmouth College | Pyridyl analogs of 1-(2-cyano-3,12-dioxooleana-1,9(11)dien-28-oyl) imidazole |
US9896475B2 (en) | 2014-08-26 | 2018-02-20 | Trustees Of Dartmouth College | Pyridyl analogs of 1-(2-cyano-3,12-dioxooleana-1,9(11)dien-28-oyl) imidazole |
WO2016039359A1 (ja) | 2014-09-10 | 2016-03-17 | 第一三共株式会社 | 眼疾患治療用及び予防用徐放性医薬組成物 |
KR20240035818A (ko) | 2015-02-12 | 2024-03-18 | 리아타 파마슈티컬즈, 아이엔씨. | 항산화 염증 조절제로서의 이미다졸릴 트리사이클릭 에논 |
KR20180061251A (ko) | 2015-09-23 | 2018-06-07 | 리아타 파마슈티컬즈, 아이엔씨. | Il-17의 저해를 위한 c4-변형된 올레아놀산 유도체 및 다른 용도 |
KR102475130B1 (ko) * | 2016-03-31 | 2022-12-07 | (주)아모레퍼시픽 | 펜타사이클릭 트리터펜 카페익 액씨드 에스터를 포함하는 피부 보습 또는 피부 미백용 조성물 |
KR102486434B1 (ko) | 2016-11-08 | 2023-01-09 | 리아타 파마슈티컬즈 홀딩스, 엘엘씨 | 바독솔론 메틸 또는 이의 유사체를 사용하는 알포트 증후군의 치료 방법 |
TWI831738B (zh) | 2016-12-16 | 2024-02-11 | 美商瑞塔醫藥有限責任公司 | 用於抑制RORγ及其他用途的嘧啶三環烯酮衍生物 |
JP6820450B2 (ja) | 2017-09-14 | 2021-01-27 | フェニックス・バイオテクノロジー・インコーポレイテッド | ウイルス感染を治療するための方法および組成物 |
KR20200083969A (ko) | 2017-09-14 | 2020-07-09 | 피닉스 바이오테크놀러지 인코포레이티드. | 신경학적 상태를 치료하기 위한 방법 및 개선된 신경보호 조성물 |
US10137138B1 (en) | 2018-05-29 | 2018-11-27 | King Saud University | Sulfonylurea derivatives of oleanolic acid |
US11993574B2 (en) | 2018-06-15 | 2024-05-28 | Reata Pharmaceuticals, Inc | Pyrazole and imidazole compounds for inhibition of IL-17 and RORgamma |
AU2020218255A1 (en) * | 2019-02-07 | 2021-09-09 | Ardelyx, Inc. | Glycyrrhetinic acid derivatives for use in treating hyperkalemia |
KR20220116209A (ko) * | 2019-12-19 | 2022-08-22 | 리아타 파마슈티컬즈, 아이엔씨. | C-17에서 질소 기반 치환기를 갖는 합성 트리테르페노이드 및 이의 사용 방법 |
CN111205346B (zh) * | 2020-02-10 | 2022-01-28 | 中国药科大学 | 齐墩果酸的衍生物及其医药用途 |
SG11202105728YA (en) | 2020-03-31 | 2021-11-29 | Phoenix Biotechnology Inc | Method and compositions for treating coronavirus infection |
EP4009981B1 (en) | 2020-03-31 | 2023-08-16 | Phoenix Biotechnology, Inc. | Method and compositions for treating coronavirus infection |
WO2021202720A1 (en) * | 2020-04-01 | 2021-10-07 | Fronthera U.S. Pharmaceuticals Llc | Use of triterpenoid nrf2 inhibitors |
US20230255982A1 (en) | 2020-05-09 | 2023-08-17 | Reata Pharmaceuticals Holdings, LLC | Methods of treating covid-19 using bardoxolone methyl or analogs thereof |
EP4259155A1 (en) | 2020-12-11 | 2023-10-18 | Reata Pharmaceuticals Holdings, LLC | Synthetic triterpenoids for use in therapy |
EP4277916A1 (en) | 2021-01-18 | 2023-11-22 | Reata Pharmaceuticals, Inc. | Synthetic ursolic acid derivatives and methods of use thereof |
CN115626947B (zh) * | 2022-09-27 | 2024-07-02 | 中山大学 | 五环三萜类天然产物的合成及其应用 |
CN115501237B (zh) * | 2022-10-27 | 2023-09-05 | 五邑大学 | 齐墩果酸衍生物在制备抑菌药物中的应用 |
Family Cites Families (95)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1435622A (en) | 1973-11-07 | 1976-05-12 | Biorex Laboratories Ltd | Erythrodiol derivatives |
JPS5555153U (lt) | 1978-10-06 | 1980-04-14 | ||
US4395423A (en) * | 1978-10-10 | 1983-07-26 | Sterling Drug Inc. | Polycyclic cyanoketones |
US4634208A (en) | 1983-01-31 | 1987-01-06 | Amp Incorporated | Electrical plug connector and method of terminating a cable therewith |
US4526988A (en) * | 1983-03-10 | 1985-07-02 | Eli Lilly And Company | Difluoro antivirals and intermediate therefor |
DE3321117A1 (de) | 1983-06-10 | 1984-12-13 | Siemens AG, 1000 Berlin und 8000 München | Magnetische multipolanordnung n-ter ordnung |
ATE92499T1 (de) * | 1984-12-04 | 1993-08-15 | Lilly Co Eli | Tumorbehandlung bei saeugetieren. |
US4635208A (en) | 1985-01-18 | 1987-01-06 | Hewlett-Packard Company | Computer-aided design of systems |
US4636308A (en) | 1985-06-13 | 1987-01-13 | Summers Don D | Method and apparatus for reclaiming drilling fluids from undesirable solids in a drilling operation |
US4636608A (en) | 1985-11-15 | 1987-01-13 | Benteler Corporation | Laser contour cut door beams |
US5013649A (en) * | 1986-07-01 | 1991-05-07 | Genetics Institute, Inc. | DNA sequences encoding osteoinductive products |
RU1787160C (ru) | 1986-12-24 | 1993-01-07 | Эли Лилли Энд Компани | Способ получени иммуноглобулинового конъюгата |
ES2075040T3 (es) | 1988-02-16 | 1995-10-01 | Lilly Co Eli | 2',3'-dideoxi-2',2'-difluoronucleosidos. |
US5443826A (en) | 1988-08-02 | 1995-08-22 | Borody; Thomas J. | Treatment of gastro-intestinal disorders with a fecal composition or a composition of bacteroides and E. Coli |
US5064823A (en) * | 1988-08-24 | 1991-11-12 | Research Triangle Institute | Pentacyclic triterpenoid compounds as topoisomerase inhibitors or cell differentiation inducers |
CA2004695C (en) | 1988-12-12 | 1999-08-10 | Rosanne Bonjouklian | Phospholipid nucleosides |
CA2079796A1 (en) | 1990-04-04 | 1991-10-05 | Jo Klaveness | Nucleoside derivatives |
SE502569C2 (sv) * | 1991-05-31 | 1995-11-13 | British Tech Group | Användning av en immunologiskt inert matris av en sterol och saponiner som kan bilda sfäriska nanopartiklar med snäv storleksfördelning som läkemedelsbärare, partiklar, komposition samt kit |
YU43193A (sh) | 1992-06-22 | 1997-01-08 | Eli Lilly And Company | 2'-deoksi-2',2'-difluoro(4-supstituisani)pirimidinski nukleozidi antivirusnog i antikancerogenog dejstva i međuproizvodi |
US5426183A (en) * | 1992-06-22 | 1995-06-20 | Eli Lilly And Company | Catalytic stereoselective glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides |
US5606048A (en) * | 1992-06-22 | 1997-02-25 | Eli Lilly And Company | Stereoselective glycosylation process for preparing 2'-Deoxy-2', 2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides |
US5401838A (en) * | 1992-06-22 | 1995-03-28 | Eli Lilly And Company | Stereoselective fusion glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides |
UA41261C2 (uk) | 1992-06-22 | 2001-09-17 | Елі Ліллі Енд Компані | Спосіб одержання збагачених бета-аномером нуклеозидів |
DE4308042C2 (de) * | 1993-03-13 | 2000-10-12 | Alstom Energy Syst Gmbh | Wälzmühle |
US6025395A (en) * | 1994-04-15 | 2000-02-15 | Duke University | Method of preventing or delaying the onset and progression of Alzheimer's disease and related disorders |
US5972703A (en) * | 1994-08-12 | 1999-10-26 | The Regents Of The University Of Michigan | Bone precursor cells: compositions and methods |
US5599795A (en) | 1994-08-19 | 1997-02-04 | Mccann; Michael | Method for treatment of idiopathic inflammatory bowel disease (IIBD) |
US5521294A (en) * | 1995-01-18 | 1996-05-28 | Eli Lilly And Company | 2,2-difluoro-3-carbamoyl ribose sulfonate compounds and process for the preparation of beta nucleosides |
EP0909184B1 (en) | 1996-07-03 | 2003-09-17 | PHARMACIA & UPJOHN COMPANY | Targeted drug delivery using sulfonamide derivatives |
KR100483256B1 (ko) | 1997-01-24 | 2005-04-15 | 콘파마 아에스 | 젬시타빈 유도체 |
US20050276836A1 (en) * | 1997-06-11 | 2005-12-15 | Michelle Wilson | Coated vaginal devices for vaginal delivery of therapeutically effective and/or health-promoting agents |
US5965119A (en) | 1997-12-30 | 1999-10-12 | Enzon, Inc. | Trialkyl-lock-facilitated polymeric prodrugs of amino-containing bioactive agents |
US6326507B1 (en) * | 1998-06-19 | 2001-12-04 | Trustees Of Dartmouth College | Therapeutic compounds and methods of use |
US6369101B1 (en) | 1999-02-26 | 2002-04-09 | Regents Of The University Of Minnesota | Therapeutic method to treat herpes virus infection |
US6485756B1 (en) * | 1999-04-06 | 2002-11-26 | Collaborative Technologies, Inc. | Stable, homogeneous natural product extracts containing polar and apolar fractions |
MXPA01011613A (es) | 1999-05-14 | 2003-10-14 | Nereus Pharmaceuticals Inc | Nuevos moduladores de interleucina-1 y factor-alfa de necrosis tumoral, sistesis de dichos moduladores y metodos de utilizar dichos moduladores. |
ES2298146T3 (es) | 1999-06-25 | 2008-05-16 | Roche Diagnostics Operations, Inc. | Inmunoensayo de inhibicion de enzimas. |
US6649654B1 (en) | 1999-11-23 | 2003-11-18 | The Regents Of The University Of California | Methods for identifying and using IKK inhibitors |
JP2001240573A (ja) * | 2000-03-01 | 2001-09-04 | Meiji Seika Kaisha Ltd | トリテルペン誘導体及び肝疾患治療剤 |
WO2002003996A1 (en) | 2000-07-12 | 2002-01-17 | RAJKUMAR, Sujatha | Use of dammarane-type tritepenoid saporins |
US6951847B2 (en) | 2000-09-29 | 2005-10-04 | Regents Of The University Of Minnesota | Methods of treating fungal infections using lupeol |
US6642217B2 (en) | 2000-09-29 | 2003-11-04 | Naturtek, Llc | Triterpenes having human antifungal and antiyeast activity |
WO2002026762A1 (en) * | 2000-09-29 | 2002-04-04 | Regents Of The University Of Minnesota | Triterpenes having antibacterial activity |
US6878751B1 (en) | 2000-10-19 | 2005-04-12 | Imperial College Of Science Technology And Medicine | Administration of resveratrol to treat inflammatory respiratory disorders |
EP1395255A4 (en) | 2000-11-28 | 2007-09-12 | Univ Texas | CDDO COMPOUNDS AND COMBINATION THERAPIES THEREOF |
US7435755B2 (en) * | 2000-11-28 | 2008-10-14 | The Trustees Of Dartmouth College | CDDO-compounds and combination therapies thereof |
AU2002308701A1 (en) | 2001-05-14 | 2002-11-25 | University Of Maryland, Baltimore | Novel alanine transaminase enzyme and methods of use |
US6794801B2 (en) | 2001-10-31 | 2004-09-21 | Toshiba Lighting & Technology Corporation | Compact selfballasted fluorescent lamp and luminaire |
MXPA04004882A (es) | 2001-11-23 | 2005-04-11 | Chugai Pharmaceutical Co Ltd | Metodo para la identificacion de enzimas que tienen como objetivo tumores. |
WO2003059339A1 (en) | 2002-01-15 | 2003-07-24 | Trustees Of Dartmouth College | Tricyclic-bis-enone derivatives and methods of use thereof |
EP1465914B1 (en) | 2002-01-18 | 2008-12-17 | Regents Of The University Of Minnesota | Triterpene quaternary salts as biologically active surfactants |
CA2485565A1 (en) | 2002-05-13 | 2004-08-05 | Trustees Of Dartmouth College | Inhibitors and methods of use thereof |
US7265096B2 (en) * | 2002-11-04 | 2007-09-04 | Xenoport, Inc. | Gemcitabine prodrugs, pharmaceutical compositions and uses thereof |
WO2004089357A2 (en) | 2003-04-02 | 2004-10-21 | Regents Of The University Of Minnesota | Anti-fungal formulation of triterpene and essential oil |
US20050208151A1 (en) | 2003-10-30 | 2005-09-22 | Entelos, Inc. | Treatment of rheumatoid arthritis with FLIP antagonists |
US8288439B2 (en) | 2003-11-04 | 2012-10-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods and compositions for the inhibition of HIV-1 replication |
DE602004005617T2 (de) | 2003-12-22 | 2007-12-13 | Alcon Inc. | Mittel zur behandlung von glaukomatöser retinopathie und optischer neuropathie |
US20060258752A1 (en) | 2004-02-12 | 2006-11-16 | Vander Jagt David L | Method and compounds for cancer treatment utilizing NFkB as a direct or ultimate target for small molecule inhibitors |
JP2005314381A (ja) | 2004-03-30 | 2005-11-10 | Anges Mg Inc | 増殖性腎疾患の予防・治療・改善剤 |
CA2579231C (en) | 2004-09-07 | 2018-07-10 | Pacific Arrow Limited | Anti-tumor compounds with angeloyl groups |
US7714726B2 (en) | 2005-05-06 | 2010-05-11 | Dominic M. Kotab | Semi-transparent RFID tags |
JP2006347952A (ja) * | 2005-06-16 | 2006-12-28 | Yoshihiro Futamura | リパーゼ活性化作用を呈するアントラキノン誘導体、それからなる抗肥満薬、食品製剤及び化粧品 |
EP1959969A2 (en) | 2005-07-01 | 2008-08-27 | The Johns Hopkins University | Compositions and methods for the treatment or prevention of disorders relating to oxidative stress |
DE102005041613A1 (de) | 2005-09-01 | 2007-03-08 | Ergonex Pharma Gmbh | Pharmazeutische Zusammensetzungen zur Behandlung von Karzinoid-Syndrom |
CA2633033C (en) | 2005-12-12 | 2016-11-22 | Mosamedix B.V. | Annexin derivatives suitable for pretargeting in therapy and diagnosis |
US20070232577A1 (en) | 2006-03-23 | 2007-10-04 | Advanced Life Sciences, Inc. | Synthetic pentacyclic triterpenoids and derivatives of betulinic acid and betulin |
US20070249561A1 (en) | 2006-04-25 | 2007-10-25 | Taylor Bradley K | Pharmacological method for treatment of neuropathic pain |
WO2008000068A1 (en) | 2006-06-27 | 2008-01-03 | Wellington Laboratories Inc. | Method for preparing 2-iodo triterpenoid compounds |
CN101117348B (zh) * | 2006-08-01 | 2010-12-29 | 浙江海正药业股份有限公司 | A环和c环多氧化取代的五环三萜及其制备方法和用途 |
WO2008016095A1 (fr) | 2006-08-02 | 2008-02-07 | Santen Pharmaceutical Co., Ltd. | REMÈDE PRÉVENTIF OU CURATIF POUR LES KÉRATOCONJONCTIVITES CONTENANT UN ACTIVATEUR DE Nrf2 EN TANT QUE MATIÈRE ACTIVE |
JP2008110962A (ja) | 2006-08-02 | 2008-05-15 | Santen Pharmaceut Co Ltd | Nrf2活性化物質を有効成分として含む角結膜障害の予防または治療剤 |
WO2008063318A2 (en) | 2006-10-12 | 2008-05-29 | The Texas A & M University System And Safe Et Al | Betulinic acid, derivatives and analogs thereof and uses therefor |
WO2008064133A1 (en) | 2006-11-17 | 2008-05-29 | Trustees Of Dartmouth College | Synthesis and biological activities of new tricyclic-bis-enones (tbes) |
US8299046B2 (en) * | 2006-11-17 | 2012-10-30 | Trustees Of Dartmouth College | Synthetic triterpenoids and tricyclic-bis-enones for use in stimulating bone and cartilage growth |
HRP20220902T3 (hr) | 2007-02-08 | 2022-10-14 | Biogen Ma Inc. | Pripravci i njihova upotreba u liječenju multiple skleroze |
WO2008111497A1 (ja) | 2007-03-08 | 2008-09-18 | Santen Pharmaceutical Co., Ltd. | トリテルペノイドを有効成分として含有する酸化ストレスが関連する眼疾患の予防又は治療剤 |
WO2008136838A1 (en) | 2007-05-04 | 2008-11-13 | Trustees Of Dartmouth College | Novel amide derivatives of cddo and methods of use thereof |
US8088824B2 (en) | 2007-08-15 | 2012-01-03 | Reata Pharmaceuticals Inc. | Forms of CDDO methyl ester |
US20090048205A1 (en) * | 2007-08-15 | 2009-02-19 | Colin Meyer | Combination therapy with synthetic triterpenoids and gemcitabine |
US9012439B2 (en) | 2007-10-29 | 2015-04-21 | University Of Rochester | Use of electrophilic compounds for inducing platelet production or maintaining platelet function |
WO2009089545A1 (en) | 2008-01-11 | 2009-07-16 | Reata Pharmaceuticals, Inc. | Synthetic triterpenoids and methods of use in the treatment of disease |
BRPI0911422B8 (pt) | 2008-04-18 | 2021-05-25 | Reata Pharmaceuticals Inc | compostos moduladores inflamatórios antioxidantes, composição farmacêutica e usos dos mesmos |
MX2010011435A (es) | 2008-04-18 | 2011-01-25 | Reata Pharmaceuticals Inc | Compuestos que incluyen un nucleo farmaceutico antiinflamatorio y sus metodos de uso. |
WO2009146216A2 (en) | 2008-04-18 | 2009-12-03 | Reata Pharmaceuticals. Inc. | Antioxidant inflammation modulators: novel derivatives of oleanolic acid |
CA2721838C (en) | 2008-04-18 | 2017-05-23 | Reata Pharmaceuticals, Inc. | Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at c-17 |
CN102164941B (zh) | 2008-04-18 | 2015-05-27 | 里亚塔医药公司 | 抗氧化剂炎症调节剂:具有饱和c环的齐墩果酸衍生物 |
JP5758801B2 (ja) | 2008-07-22 | 2015-08-05 | トラスティーズ・オブ・ダートマス・カレッジTrustees of Dartmouth College | 単環式シアノエノンおよびその使用方法説明 |
US8778990B2 (en) | 2008-11-04 | 2014-07-15 | Trustees Of Dartmouth College | Betulinic acid derivatives and methods of use thereof |
PL3254675T3 (pl) | 2009-02-13 | 2019-09-30 | Reata Pharmaceuticals, Inc. | Kompozycje doustne o opóźnionym uwalnianiu, zawierające amorficzny cddo-me |
RU2401273C1 (ru) | 2009-03-30 | 2010-10-10 | Новосибирский институт органической химии им. Н.Н. Ворожцова Сибирского отделения Российской академии наук (НИОХ СО РАН) (статус государственного учреждения) | Противоопухолевое средство тритерпеновой природы, полученное путем модификации глицирретовой кислоты |
KR101819699B1 (ko) | 2010-04-12 | 2018-01-17 | 리아타 파마슈티컬즈, 아이엔씨. | 항산화성 염증 조절제를 이용하여 비만을 치료하는 방법 |
MY162186A (en) | 2011-01-31 | 2017-05-31 | Viiv Healthcare Uk (No 4) Ltd | C-17 and c-3 modified triterpenoids with hiv maturation inhibitory activity |
MX348862B (es) | 2011-03-11 | 2017-07-03 | Reata Pharmaceuticals Inc | Derivados c4-monometil triterpenoides y sus metodos de uso. |
CN208692323U (zh) | 2018-08-13 | 2019-04-05 | 深圳市优维尔科技有限公司 | 一种抽吸装置 |
US11133308B2 (en) | 2019-05-03 | 2021-09-28 | International Business Machines Corporation | Uniform work function metal recess for vertical transistor complementary metal oxide semiconductor technology |
-
2009
- 2009-04-20 BR BRPI0911422A patent/BRPI0911422B8/pt active IP Right Grant
- 2009-04-20 PT PT97327696T patent/PT2271658T/pt unknown
- 2009-04-20 WO PCT/US2009/041176 patent/WO2009129548A1/en active Application Filing
- 2009-04-20 TW TW098113097A patent/TWI584808B/zh active
- 2009-04-20 LT LTEP09732769.6T patent/LT2271658T/lt unknown
- 2009-04-20 CN CN201410370080.XA patent/CN104250280A/zh active Pending
- 2009-04-20 MX MX2010011439A patent/MX2010011439A/es active IP Right Grant
- 2009-04-20 AU AU2009237581A patent/AU2009237581C1/en active Active
- 2009-04-20 KR KR20107025718A patent/KR20110010611A/ko not_active Application Discontinuation
- 2009-04-20 SI SI200931602A patent/SI2271658T1/sl unknown
- 2009-04-20 ME MEP-2017-27A patent/ME02751B/me unknown
- 2009-04-20 DK DK09732769.6T patent/DK2271658T3/en active
- 2009-04-20 RS RS20170078A patent/RS55631B1/sr unknown
- 2009-04-20 CN CN200980123243.1A patent/CN102066398B/zh active Active
- 2009-04-20 EA EA201001554A patent/EA020156B1/ru unknown
- 2009-04-20 HU HUE09732769A patent/HUE033288T2/en unknown
- 2009-04-20 PL PL09732769T patent/PL2271658T3/pl unknown
- 2009-04-20 EP EP09732769.6A patent/EP2271658B1/en active Active
- 2009-04-20 US US12/426,832 patent/US7943778B2/en active Active
- 2009-04-20 CA CA2721666A patent/CA2721666C/en active Active
- 2009-04-20 KR KR1020167029864A patent/KR101782020B1/ko active IP Right Grant
- 2009-04-20 JP JP2011505260A patent/JP5588966B2/ja active Active
- 2009-04-20 NZ NZ58871109A patent/NZ588711A/xx unknown
- 2009-04-20 ES ES09732769.6T patent/ES2613964T3/es active Active
-
2010
- 2010-10-17 IL IL208759A patent/IL208759B/en active IP Right Grant
- 2010-10-25 ZA ZA2010/07589A patent/ZA201007589B/en unknown
- 2010-11-18 CO CO10144468A patent/CO6311107A2/es active IP Right Grant
-
2011
- 2011-02-23 US US13/033,475 patent/US8394967B2/en active Active
- 2011-07-04 HK HK11106765A patent/HK1152713A1/xx unknown
-
2013
- 2013-01-14 US US13/741,072 patent/US9249089B2/en active Active
-
2014
- 2014-07-28 JP JP2014152564A patent/JP2015028019A/ja active Pending
- 2014-09-11 AU AU2014224098A patent/AU2014224098A1/en not_active Abandoned
-
2015
- 2015-05-07 HK HK15104353.6A patent/HK1203968A1/xx unknown
-
2017
- 2017-01-23 HR HRP20170102TT patent/HRP20170102T1/hr unknown
- 2017-01-23 CY CY20171100090T patent/CY1118475T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1203968A1 (en) | Antioxidant inflammation modulators: c-17 homologated oleanolic acid derivatives :c-17 | |
HRP20182060T1 (hr) | Antioksidantni modulatori upale: derivati oleanolne kiseline s amino i drugim modifikacijama na c-17 | |
ZA201007590B (en) | Antioxidant inflammation modulators:oleanolic acid derivatives with saturation in the c-ring | |
HRP20181266T1 (hr) | Kortikosteroidni pripravci za oralnu primjenu | |
ZA201202711B (en) | Nutritional compositions for modulating inflammation including exogenous vitamin k2 | |
EP2305307A4 (en) | ANALGESIC ANTI-INFLAMMATORY PREPARATION FOR EXTERNAL APPLICATION | |
GB0604535D0 (en) | Betulonic acid derivatives | |
EP2518040A4 (en) | Low-viscosity liquid-crystal compound | |
HK1186963A1 (zh) | 含有齊墩果酸的化妝品組合物 | |
EP2475251A4 (en) | HYALURONANE / STABLE STEROID FORMULATION | |
EP2303279A4 (en) | TOPICAL STEROIDAL FORMULATIONS | |
IL206069A0 (en) | Phenyl acetic acid derivatives as inflammation modulators | |
ZA201007257B (en) | Steroid nebuliser formulation | |
GB0806802D0 (en) | Conjugated linoleic acid derivatives | |
AU2014233629B2 (en) | Orally administered corticosteroid compositions | |
GB2465746B (en) | Pharmaceutical composition for topical application | |
BRPI0911457A2 (pt) | moduladores inflamatórios antioxidantes; ácido oleanólico derivados com amina e outras modificações em c-17 | |
IL220512A0 (en) | Compositions for topical administration | |
AU2008904268A0 (en) | Compound with synergistic antioxidant and anti-inflammatory effect |